The hemolytic uremic syndrome (HUS) is one of the thrombotic microangiopathies and it consists of the triad of nonimmune microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. The atypical form of HUS (aHUS) is related to causative mutations in complement genes. Some conditions act as a trigger for aHUS in individuals that have a genetic background predisposing to complement activation. Interferon β is a recombinant-protein therapy approved to treat multiple sclerosis (MS), and can be a causative agent in the occurrence of HUS through anti-angiogenic activity. In this paper, we briefly review aHUS clinical and genetic characteristics. Furthermore, we present a case of a 48-year-old woman, diagnosed with MS and treated with INFβ-1b from 2008. In December 2015, she presented with asthenia and loss of muscular strength in the legs and she quickly developed aHUS. Our case suggests that INFβ is a possible triggering factor for HUS.

1.
KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl (2011) 2012;2:6.
2.
Zheng XL, Sadler JE: Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008;3:249-277.
3.
Sawai T, Nangaku M, Ashida A, Fujimaru R, Hataya H, Hidaka Y, Kaname S, Okada H, Sato W, Yasuda T, Yoshida Y, Fujimura Y, Hattori M, Kagami S: Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Pediatr Int 2014;56:1-5.
4.
Nester CM, Thomas CP: Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology Am Soc Hematol Educ Program 2012;2012:617-625.
5.
Laurence J: Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv Hematol Oncol 2012;10(10 suppl 17):1-12.
6.
Ardissino G, Possenti I, Tel F, Testa S, Paglialonga F: Time to change the definition of hemolytic uremic syndrome. Eur J Intern Med 2014;25:e29.
7.
Loirat C, Fremeaux-Bacchi V: Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60.
8.
Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM: Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009;361:345-357.
9.
Noris M, Remuzzi G: Atypical hemolytic-uremic syndrome. N Engl J Med 2009;361:1676-1687.
10.
Sanchez Chinchilla D, Pinto S, Hoppe B, Adragna M, Lopez L, Justa Roldan ML, Pena A, Lopez Trascasa M, Sanchez-Corral P, Rodriguez de Cordoba S: Complement mutations in diacylglycerol kinase-ε-associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2014;9:1611-1619.
11.
Bu F, Maga T, Meyer NC, Wang K, Thomas CP, Nester CM, Smith RJ: Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2014;25:55-64.
12.
Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G: Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5:1844-1859.
13.
Rafiq A, Tariq H, Abbas N, Shenoy R: Atypical hemolytic-uremic syndrome: a case report and literature review. Am J Case Rep 2015;16:109-114.
14.
Cataland SR, Wu HM: Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies. Eur J Intern Med 2013;24:486-491.
15.
Noris M, Remuzzi G: Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015. Am J Kidney Dis 2015;66:359-375.
16.
Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C: Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015;87:1061-1073.
17.
Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A: A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open 2013;3:e003573.
18.
Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G: Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014;12:1440-1448.
19.
Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G: Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014;124:1715-1726.
20.
Palma LM, Langman CB: Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med 2016;7:39-72.
21.
Bridel C, Lalive PH: Update on multiple sclerosis treatments. Swiss Med Wkly 2014;144:w14012.
22.
Kawaji H, Tokuyama T, Yamasaki T, Amano S, Sakai N, Namba H: Interferon-β and temozolomide combination therapy for temozolomide monotherapy-refractory malignant gliomas. Mol Clin Oncol 2015;3:909-913.
23.
Wolpert F, Happold C, Reifenberger G, Florea AM, Deenen R, Roth P, Neidert MC, Lamszus K, Westphal M, Weller M, Eisele G: Interferon-β modulates the innate immune response against glioblastoma initiating cells. PLoS One 2015;10:e0139603.
24.
Tolley K, Hutchinson M, You X, Wang P, Sperling B, Taneja A, Siddiqui MK, Kinter E: A network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon beta-1a versus other injectable therapies for the treatment of relapsing-remitting multiple sclerosis. PLoS One 2015;10:e0127960.
25.
Ben-Amor AF, Trochanov A, Fischer TZ: Cumulative review of thrombotic microangiopathy, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome reports with subcutaneous interferon β-1a. Adv Ther 2015;32:445-454.
26.
Ontaneda D, Di Capua D: Benefits versus risks of latest therapies in multiple sclerosis: a perspective review. Ther Adv Drug Saf 2012;3:291-303.
27.
Mahe J, Meurette A, Moreau A, Vercel C, Jolliet P: Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis. Drug Des Devel Ther 2013;7:723-728.
28.
Sullivan M, Erlic Z, Hoffmann MM, Arbeiter K, Patzer L, Budde K, Hoppe B, Zeier M, Lhotta K, Rybicki LA, Bock A, Berisha G, Neumann HP: Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet 2010;74:17-26.
29.
Francis NJ, McNicholas B, Awan A, Waldron M, Reddan D, Sadlier D, Kavanagh D, Strain L, Marchbank KJ, Harris CL, Goodship TH: A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood 2012;119:591-601.
30.
Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook HT, de Cordoba SR, Botto M: Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007;204:1249-1256.
31.
Manenti L, Gnappi E, Vaglio A, Allegri L, Noris M, Bresin E, Pilato FP, Valoti E, Pasquali S, Buzio C: Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrol Dial Transplant 2013;28:2246-2259.
32.
Bendapudi PK, Makar RS: An algorithmic approach to the diagnosis and management of the thrombotic microangiopathies. Am J Clin Pathol 2016;145:152-154.
33.
Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V: Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012;8:643-657.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.